SanionaToggle sidemenu
  • About Saniona
    • Corporate Governance
      • Articles of association
      • Shareholder meetings
      • Nomination Committee
      • Board of Directors
      • Audit Committee
      • Remuneration Committee
      • Executive Management
      • Auditors
      • Corporate Governance Reports
      • Policies
      • Remuneration
    • Our Vision
    • Strategy and Business Model
  • Proprietary Pipeline
    • Tesomet
    • SAN711
    • SAN903
  • Partnered Pipeline
    • Tesofensine
    • CAD-1883
    • Boehringer Ingelheim
  • Investors
    • Share information
    • Frequently asked questions
    • Unit rights Issue 2020
    • Warrants of series TO 1
    • Warrants of series TO 2
    • Ownership structure
    • Analyst coverage
    • Financial calendar
    • Financial reports
    • Company presentations
    • Interviews & Webcasts
    • Propectus August 2020
  • News
  • Careers
    • Denmark
    • United States
  • English Swedish

    OMX: SANION 18.02 -0.99 %

  • About Saniona
    • Corporate Governance
      • Articles of Association of Saniona AB (publ) Reg. no. 556962-5345
      • Shareholder meetings
      • Nomination Committee
      • Board of Directors
      • Audit Committee
      • Remuneration Committee
      • Executive Management
      • Auditors
      • Corporate Governance Reports
      • Policies
      • Remuneration
    • Our Vision
    • Strategy and Business Model
  • Proprietary Pipeline
    • Tesomet for treatment of Prader-Willi Syndrome and Hypothalamic Obesity
    • SAN711 for the treatment of rare neuropathic disorders
    • SAN903 for rare inflammatory and fibrotic disorders
  • Partnered Pipeline
    • Tesofensine for treatment of obesity
    • CAD-1883 for treatment of tremor and spinocerebellar ataxia
    • Boehringer Ingelheim collaboration for treatment of schizophrenia
  • Investors
    • Share information
    • Frequently asked questions
    • Unit rights Issue 2020
      • Prospectus
    • Warrants of series TO 1
    • Warrants of series TO 2
    • Ownership structure
    • Analyst coverage
      • 2019 Reports
      • 2018 Reports
      • 2017 Reports
      • 2016 Reports
      • 2015 Reports
      • 2014 Reports
    • Financial calendar
    • Financial reports
    • Company presentations
    • Interviews & Webcasts
    • Propectus August 2020
      • Propectus
  • News
  • Careers
    • Denmark
    • United States
  • English Swedish

    OMX: SANION 18.02 -0.99 %

  • Home
  • Privacy policy

Saniona

Smedeland 26B 
2600 Glostrup 
Denmark

Telephone
+45 70 705 225
Email
saniona@saniona.com
Sign up to our press releases
Home Investors Unit rights Issue 2020 Prospectus

Prospectus

Prospectus 2020

Prospectus supplement

20200214 - PR - Correction ISIN

Prospectus summary (in Danish)

Warrant terms

Frequently Asked Questions

The rights issue is addressed to, on the record date, existing shareholders in Saniona. Subscription of units without unit rights is only permitted by subscribers who also have subscribed for units with support of unit rights, regardless if the subscriber was a shareholder on the record date or not.

Subscription form for subscription of units with and without unit rights in Saniona AB

Terms and conditions

Information sheet for shareholders regarding subscription of units

Investors

  • Share information
  • Frequently asked questions
  • Unit rights Issue 2020
  • Warrants of series TO 1
  • Warrants of series TO 2
  • Ownership structure
  • Analyst coverage
  • Financial calendar
  • Financial reports
  • Company presentations
  • Interviews & Webcasts
  • Propectus August 2020
  

Sign up to our press releases

Saniona
  • Home
  • Privacy policy

All Rights Reserved · Saniona · 2021

Scroll to top

Smedeland 26B 
2600 Glostrup 
Denmark

Telephone
+45 70 705 225
Email
saniona@saniona.com

500 Totten Pond Road (Suite 620)
Waltham, MA 02451
USA

Telephone
+1-781-839-9100